Epirus Gets Remicade Biosimilar Nod In India, Rollout Early 2015
This article was originally published in PharmAsia News
Executive Summary
Epirus has worked its way up speedily through the development of its biosimilar infliximab but its unique proposition is the global data package for filings in key emerging markets.